RASONQUE may be one of the most important oncology launches in years, but its long-term commercial story is far from settled. Daraxonrasib has delivered a remarkable survival benefit in metastatic pancreatic cancer, fueling multibillion-dollar sales expectations, yet emerging evidence of acquired resistance raises an uncomfortable question: how long can those sales actually last per patient? The answer could reshape everything from peak-sales forecasts and oncologist prescribing behavior to first-line treatment strategies and Revolution Medicines’ commercial priorities. The bigger opportunity may ultimately not be RASONQUE alone, but building an entire RAS franchise that keeps patients within Revolution’s portfolio as their cancer evolves and develops new escape mechanisms.
Wall Street is already treating RASONQUE as one of the biggest oncology launches in yearsMaybe it will be. But investors and pharma executives should pay very close attention to what researchers are learning about resistance to daraxonrasib, because the difference between a blockbuster and a mega-blockbuster could come down to one deceptively simple metric:
How long can patients actually stay on the drug?Duration on therapy.
RASONQUE has some amazing stats. Median OS of 13.2 months compared to chemo of 6.7 months in previously treated metastatic pancreatic cancer. FDA approved the drug back in August.
Wall Street took notice. Analysts at Evercore projected daraxonrasib sales of $1.76 billion in 2027. Others, such as Guggenheim, believe it could reach ~$900M in 2027 and then $2.2B in 2028. Visible Alpha had consensus estimates for daraxonrasib sales of roughly $10.7B by 2035.
These are pretty impressive numbers to expect from a company with its first commercial drug. Which brings me to resistance. We’ll need to know more about what’s causing it, and it could affect how much revenue RASONQUE generates.
How much can RASONQUE sell?
RASONQUE has a reported list price of $39,800/month. Annualizing that comes out to approximately $478,000. However, if we annualize the cost of the drug, we run into problems if patients aren’t taking the drug for an entire year. Median PFS was 7.2 months in RASolute 302.
We are learning more about what is causing disease progression.
We have observed resistance in patients who progress on daraxonrasib. Its possible that when you inhibit RAS with a drug like daraxonrasib, you are placing selective pressure on these pancreatic cancers to grow. Maybe they aren’t growing independent of RAS, but are turning it back on at higher levels.
This matters because if patients only take RASONQUE for a few months, peak sales will not equal the number of eligible patients x $478,000. How long patients stay on therapy will be key to understanding RASONQUE’s potential peak sales. And will likely be one of the bigger numbers that Revolution discloses to investors in the future.
Oncologists will want to know…
How soon can I start my patients on RASONQUE?
Should I hold off until second line?
Can I start them on it if they are not good candidates for combo chemo?
Should I give it with chemo?
What do I do when my patient becomes resistant?
Will I be able to know what type of resistance they developed and treat them with another RAS-targeted therapy?
These are questions oncologists will have, and they will affect the drug’s sales potential.
One thing that works in Revolution’s favor is that they gained approval for RASONQUE in patients who were not candidates for multiagent systemic therapy. This could allow oncologists to use it earlier in certain patients.
Moving to first-line will open up RASONQUE’s potential
I believe Revolution knows this, which is why they are looking to use RASONQUE in the untreated setting. Both as monotherapy and in combination with gem/nab-paclitaxel. The FDA even gave the combo Breakthrough Therapy Designation recently.
This is where peak sales numbers begin to look more plausible. If RASONQUE can be used in first-line, many more patients will be eligible for treatment. Plus, using it in combination may help delay resistance. Which is why they are testing RASONQUE +/- chemo vs chemo in RASolute 303. A phase 3 trial looking at patients with previously untreated metastatic pancreatic cancer.
If RASONQUE + chemo shows improved PFS/OS, then it could become the standard of care for pancreatic cancer. That would make it more than just another drug for pancreatic cancer. It could be the drug that all treatments revolve around. That’s a big difference.
Don’t just think about one drug
Another reason why I think learning more about resistance will be important. Don’t try to fight resistance and continue selling only RASONQUE. Learn from it and capitalize on patients who may develop resistance.
As mentioned before, multiple RAS inhibitors are in development. Daraxonrasib is the pan-RAS inhibitor. They also have zoldonrasib, which targets mutant RAS(ON) G12D, and elironrasib which targets RAS G12C. Revolution could continue to build out its pipeline with more RAS-directed therapies. That is why analysts are starting to view Revolution as more than a single-product company.
Think about it. If we can figure out what resistance mechanisms patients develop on RASONQUE, we could use that information to pick the next RAS therapy to give them. Patients would receive RASONQUE + chemo. Then, once resistance develops, we monitor for changes. Detect resistance and use another RAS therapy or possibly a combo.
All of a sudden resistance doesn’t hurt peak sales of RASONQUE. It’s another opportunity to make money off your patient. Revolution should look to do this with all of their drugs.
One final thing to consider… Community oncology
Oncologists at academic medical centers will probably be eager to prescribe RASONQUE. After all, it doubled median OS. But what about community oncology?
According to Revolution, about 60% of patients with pancreatic cancer are seen in community oncology. So they have started to hire field-based sales reps and MSLs to get out in front of the market.
I think this will be critical to their success with RASONQUE.
They will need to not only sell the drug but educate physicians on the science behind it. As we learn more about resistance and potentially move into first-line combos. Physicians will need to understand RAS biology and how to properly manage patients on these therapies.
I believe the MSL team will play a big role in RASONQUE reaching its peak sales potential. However, when they were looking for MSLs, I heard from many candidates with stellar backgrounds in cancer and Oncology who weren’t even given consideration for the openings.
Like other precision oncology drugs that require physicians to test for a mutation before prescribing, you need to change physician behavior to sell these types of drugs. You need MSLs with extensive experience working with oncologists and deep relationships, not an army ready to carry out orders.
What about the price?
$39,800/month will catch payers’ attention. Especially if RASONQUE starts to be used earlier in the treatment line. I think we will see more discussions about economics when it comes to RASONQUE in the first-line setting. Especially if it is used in combination with chemo.
Will we see health economic models? Will payers demand data showing that RASONQUE + chemo improves survival vs chemo alone? These are all questions that will come up as the drug moves to first line.
I don’t believe another pharma company will beat RASONQUE anytime soon. I think its biggest enemy will be resistance and follow-up data with broader use.
Pancreatic cancer is a very resilient disease. We now know that we can target RAS and live longer. But we are beginning to see that these cancers can overcome RAS inhibition. So when thinking about RASONQUE, I don’t think we should focus on market share alone.
We should look at how many patients are started on RASONQUE in first-line. How long patients can stay on therapy. If it’s used in combo, and how many patients can continue treatment with Revolution’s RAS franchise after they become resistant.
Those metrics will determine whether RASONQUE becomes a multi-billion-dollar drug or just a stepping stone to Revolution’s RAS franchise. Resistance could lower RASONQUE’s peak sales but within its pharmacology are additional opportunities.
